Topics:
Gastrointestinal Cancers • Medical Oncology
Do you offer nivolumab for metastatic HCC in the second line or if sorafenib is intolerable?
Currently, nivolumab is approved as a second line systemic therapy for patients with metastatic HCC with Child-Pugh (CP) A-B7 based on results from CheckMate 040. Would you consider this treatment in patients with appropriate PS but with CP-C?
Answer from: Medical Oncologist at Academic Institution
Using nivolumab in second line if the patient cannot tolerate sorafenib is appropriate; the regorefanib RESORCE trial had selected patients who tolerated sorafenib at a minimum dose of 400 mg daily for 20 of the 28 days prior to study entry.The challenge is the child pugh C status of the patient. We...
Sign in or Register to read more